TNSN03050A1 - Derives d'amides de thiazolyl -, oxazolyl - pyrrolyl - et imidazolyl - acides utiles comme inhibiteurs d' isozymes pde4. - Google Patents
Derives d'amides de thiazolyl -, oxazolyl - pyrrolyl - et imidazolyl - acides utiles comme inhibiteurs d' isozymes pde4.Info
- Publication number
- TNSN03050A1 TNSN03050A1 TNPCT/IB2001/002728A TNSN03050A TNSN03050A1 TN SN03050 A1 TNSN03050 A1 TN SN03050A1 TN SN03050 A TNSN03050 A TN SN03050A TN SN03050 A1 TNSN03050 A1 TN SN03050A1
- Authority
- TN
- Tunisia
- Prior art keywords
- equal
- group
- represent
- alkyle
- pde4 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
COMPOSES UTILES EN TANT QU* INHIBITEURS DE PDE4 DANS LE TRAITEMENT DE MALADIES, REGULEES PAR L* ACTIVATION ET LA DEGRANULATION DES CELLULES EOSINOPHILES, NOTAMMENT L “ASTHME, LA BRONCHITE CHRONIQUE, ET UNE MALADIE PULMONAIRE OBSTRUCTIVE CHRONIQUE, DE FORMULE (1) DANS LAQUELLE J EST EGAL A 0 OU I ; K EST EGAL A 0 OU I ; m EST EGAL A 0, I, 2 OU 3 ; n EST EGAL A I OU 2 W1 REPRESENTE UN GROUPE -O- ; OU C S (=0) t-, DANS LEQUEL t EGAL A 0,1, 2 ; OU CN(R3)-; W2 REPRESENTE UN GROUPE -O-CRa Rb- OU EST ABSENT ; Y REPRESENTE UN GROUPE =C(Rla) OU -[N (*(0)k|-, DANS LEQUEL k EST EGAL A 0 OU I; Ra ET Rb REPRESENTENT DES GROUPES *CH ; -F: -CF3;- (ALKYLE EN Cl A C4); CYCLOALKYLE EN C3 A Cl); PHENYLE; OU BENZYLE SUBSTITUE AVEC 0 A 3 SUBSTITUANTS RIO ; OU BIEN Ra ET Rb SONT PRIS CONJOINTEMENT, MAIS SEULEMENT DANS LE CAS OU m EST EGAL A 1, POUR FORMER UN GROUPEMENT S?\RO ; RC ET RD REPONDENT AUX DEFINITIONS DE Ra ET Rb, SAUF QU’UN D- ENTRE EUX DOIT REPRESENTER -II, RI ET R2 REPRESENTENT DES GROUPES "CH ; -F; -CI;- CN; -N02 ; -(ALKYLE EN CI-C4) ; -(ALCYNYLE EN C2 A C4); - (FLUORALKYLE EN Cl A C3) ; -ORI6 ; OU TC (=0)NR22a R22b ; R3 REPRESENTE -H; UN GROUPE C (ALKYLE EN CI-C3); PnENYLE; BENZYLE ; OU -ORI6 : OU C C(= O) NR 22a R22b ; R3 REPRESENTE CH ; UN GROUPE- (ALKYLE EN Cl A C3) ; PHENYLE ; BENZYLE ; OU C OR16 ; R4, R5 ET R6 EN PLUS D AUTRES DEFINITIONS, PEUVENT ETRE PRIS CONJOINTEMENT POUR FORMER LE COMPOSE (II);Gl REPRESENTE UN SYSTEME DE NOYAU CARBONE SATURE OU INSATURE DANS LEQUEL FACULTATIVEMENT, UN ATOME DE CARBONE PEUT ETRE REMPLACE PAR UN HETEROATOME CHOISI ENTRE N, O ET S ; G2 REPRESENTE UN SYSTEME DE NOYAU CARBONE SATURE OU INSATURE ; DANS LEQUEL UN ATOME DE CARBONE PEUT ETRE REMPLACE PAR UN HETEROATOME SELECTIONNE PARMI N, O ET S ; ET E EST CHOISI PARMI LES GROUPES DE FORMULE (III).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26548601P | 2001-01-31 | 2001-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN03050A1 true TNSN03050A1 (fr) | 2005-12-23 |
Family
ID=23010641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNPCT/IB2001/002728A TNSN03050A1 (fr) | 2001-01-31 | 2003-07-08 | Derives d'amides de thiazolyl -, oxazolyl - pyrrolyl - et imidazolyl - acides utiles comme inhibiteurs d' isozymes pde4. |
Country Status (24)
Country | Link |
---|---|
US (3) | US6559168B2 (fr) |
EP (1) | EP1355907A1 (fr) |
JP (1) | JP2004518691A (fr) |
KR (1) | KR20030072614A (fr) |
CN (1) | CN1489588A (fr) |
BG (1) | BG108039A (fr) |
BR (1) | BR0116850A (fr) |
CA (1) | CA2436551A1 (fr) |
CR (1) | CR7038A (fr) |
CZ (1) | CZ20031903A3 (fr) |
EA (1) | EA200300622A1 (fr) |
EC (1) | ECSP034683A (fr) |
EE (1) | EE200300362A (fr) |
HU (1) | HUP0401305A2 (fr) |
IL (1) | IL156412A0 (fr) |
IS (1) | IS6844A (fr) |
MA (1) | MA26985A1 (fr) |
MX (1) | MXPA03006886A (fr) |
NO (1) | NO20033398L (fr) |
OA (1) | OA12542A (fr) |
PL (1) | PL365443A1 (fr) |
TN (1) | TNSN03050A1 (fr) |
WO (1) | WO2002060898A1 (fr) |
ZA (1) | ZA200305769B (fr) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1371650A4 (fr) * | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | Activateur de recepteur active par les proliferateurs du peroxysome |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
MXPA03010679A (es) * | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Una composicion para acelerar la cicatrizacion de fractura osea. |
US20040180900A1 (en) * | 2001-05-23 | 2004-09-16 | Masaharu Takigawa | Therapeutic composition for repairing chondropathy |
EP1424078A4 (fr) * | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate |
CZ2004747A3 (cs) * | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
EP1465882B1 (fr) * | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Modulateurs heterocycliques de recepteurs nucleaires |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
WO2003063911A1 (fr) * | 2002-02-01 | 2003-08-07 | Anges Mg, Inc. | Compositions pharmaceutiques contenant un leurre et procede d'utilisation |
US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
KR101116627B1 (ko) * | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
GB0217196D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
FI114917B (fi) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
WO2004047817A1 (fr) * | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Inhibiteurs de pde4 et pde3/4 que l'on utilise dans le traitement de la cachexie |
EP1424101A3 (fr) * | 2002-11-29 | 2004-08-18 | NOZAKI, Masako | Utilisation d'un antagoniste du leucotriène c4/d4 pour la préparation d'un médicament pour le traitement ou la prévention d'une inflammation ou septicémie du cerveau |
US7148248B2 (en) * | 2002-11-29 | 2006-12-12 | Masako Nozaki | Method of treating or inhibiting the development of brain inflammation and sepsis |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US20050079548A1 (en) * | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
MXPA06002521A (es) * | 2003-09-05 | 2006-06-20 | Altana Pharma Ag | Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus. |
US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
AU2005203930C1 (en) | 2004-01-06 | 2012-02-23 | Vtv Therapeutics Llc | Heteroaryl-ureas and their use as glucokinase activators |
US20090042951A1 (en) * | 2004-02-20 | 2009-02-12 | Robert Danziger | Blood Pressure Reduction in Salt-Sensitive Hypertension |
WO2005102388A1 (fr) * | 2004-04-26 | 2005-11-03 | Ono Pharmaceutical Co., Ltd. | Nouvelle maladie médiée par blt2, et agent et composé de liaison à blt2 |
CN101031293A (zh) * | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
US7655680B2 (en) * | 2004-05-17 | 2010-02-02 | Otsuka Pharmaceutical Co., Ltd. | Thiazole compound and use thereof |
US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
CA2583428A1 (fr) * | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Inhibiteurs de la phosphodiesterase 4b (pde4b) |
US7704522B2 (en) | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
NZ560269A (en) * | 2005-03-08 | 2010-12-24 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
WO2006094942A1 (fr) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast pour le traitement du diabète sucré |
PL2366393T3 (pl) * | 2005-04-19 | 2014-01-31 | Takeda Gmbh | Roflumilast do leczenia nadciśnienia płucnego |
US7999114B2 (en) * | 2005-07-08 | 2011-08-16 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
EP2377856A1 (fr) * | 2005-07-14 | 2011-10-19 | Novo Nordisk A/S | Activateurs de la glucokinase d'urée |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP2258358A3 (fr) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenèse avec un inhibiteur de l'acetylcholinestérase |
CN1954882A (zh) | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (fr) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogénèse par modulation de l'angiotensine |
EP2026813A2 (fr) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | Neurogenèse induite par le récepteur 5ht |
AU2007283404B2 (en) * | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8138185B2 (en) * | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
MX2009007916A (es) | 2007-01-24 | 2009-07-31 | Glaxo Group Ltd | Composiciones farmaceuticas que comprenden 3,5-diamino-6-(2,3-dicl orofenil)-l,2,4,-triazina; o r(-)-2,4-diamino-5-(2,3-diclorofenil) -6-fluorometil pirimidina y un receptor neuroquinina 1. |
AU2008326385B2 (en) * | 2007-11-21 | 2013-12-05 | Decode Genetics Ehf | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
US20090269354A1 (en) * | 2008-03-28 | 2009-10-29 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
NZ593892A (en) | 2008-12-23 | 2013-11-29 | Biosource Pharm Inc | Antibiotic compositions for the treatment of gram negative infections |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
ES2568629T3 (es) * | 2009-06-18 | 2016-05-03 | Concert Pharmaceuticals Inc. | Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa |
US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
JO3264B1 (ar) * | 2013-03-13 | 2018-09-16 | Lilly Co Eli | مركبات ازيتيدينيل أوكسي فينيل بيروليدين |
RU2662806C2 (ru) * | 2013-06-12 | 2018-07-31 | Какен Фармасьютикал Ко., Лтд. | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента |
TW201625591A (zh) * | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
CN108794620A (zh) * | 2017-05-04 | 2018-11-13 | 南开大学 | 茶碱的偶联物及其制备方法与应用 |
WO2019157144A1 (fr) | 2018-02-07 | 2019-08-15 | Duke University | Système et procédé de phosphorylation du gpcr homogène et d'identification de modulateurs allostériques positifs des récepteurs bêta-2 adrénergique |
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2140772A5 (en) | 1971-06-07 | 1973-01-19 | Aries Robert | Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics |
US4270946A (en) * | 1979-10-01 | 1981-06-02 | Stauffer Chemical Company | N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof |
US4692185A (en) * | 1986-01-13 | 1987-09-08 | Stauffer Chemical Company | N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides |
US4861891A (en) | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
EP0500989B1 (fr) | 1991-02-27 | 1998-12-09 | Lacer, S.A. | Agents antihypertensifs dipeptidiques N-(pyridyl-alpha-substituée) carbonyle |
DE4200323A1 (de) | 1992-01-09 | 1993-07-15 | Bayer Ag | Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten |
MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
JPH08511805A (ja) | 1993-06-18 | 1996-12-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP3406689B2 (ja) | 1994-03-15 | 2003-05-12 | 株式会社大塚製薬工場 | ナフチリジン及びピリドピラジン誘導体 |
US5618027A (en) * | 1994-07-20 | 1997-04-08 | Nevrekar; Venkatesh R. | Gate valve |
WO1996019990A1 (fr) | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | Monomeres 4,4-(disubstitues)cyclohexan-1-carboxylate et composes correspondants |
TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US5922557A (en) | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
TR199902432T2 (xx) | 1997-04-04 | 2000-01-21 | Prizer Products Inc. | Nikotinamid t�revleri. |
GB9715584D0 (en) * | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
UA67753C2 (uk) | 1997-10-10 | 2004-07-15 | Смітклайн Бічам Корпорейшн | Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот |
AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
AR015190A1 (es) | 1997-10-23 | 2001-04-18 | Smithkline Beecham Corp | Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento |
OA12170A (en) * | 2000-01-31 | 2006-05-08 | Pfizer Prod Inc | Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes. |
EA004885B1 (ru) * | 2000-01-31 | 2004-08-26 | Пфайзер Продактс Инк. | Никотинамидные бензоконденсированные гетероциклические производные, полезные в качестве селективных ингибиторов pde4-изозимов |
-
2001
- 2001-12-24 HU HU0401305A patent/HUP0401305A2/hu unknown
- 2001-12-24 CZ CZ20031903A patent/CZ20031903A3/cs unknown
- 2001-12-24 OA OA1200300177A patent/OA12542A/en unknown
- 2001-12-24 PL PL01365443A patent/PL365443A1/xx not_active Application Discontinuation
- 2001-12-24 KR KR10-2003-7010071A patent/KR20030072614A/ko not_active Application Discontinuation
- 2001-12-24 EP EP01273600A patent/EP1355907A1/fr not_active Withdrawn
- 2001-12-24 JP JP2002561466A patent/JP2004518691A/ja active Pending
- 2001-12-24 IL IL15641201A patent/IL156412A0/xx unknown
- 2001-12-24 CA CA002436551A patent/CA2436551A1/fr not_active Abandoned
- 2001-12-24 CN CNA018224431A patent/CN1489588A/zh active Pending
- 2001-12-24 EA EA200300622A patent/EA200300622A1/ru unknown
- 2001-12-24 EE EEP200300362A patent/EE200300362A/xx unknown
- 2001-12-24 MX MXPA03006886A patent/MXPA03006886A/es active IP Right Grant
- 2001-12-24 WO PCT/IB2001/002728 patent/WO2002060898A1/fr not_active Application Discontinuation
- 2001-12-24 BR BR0116850-9A patent/BR0116850A/pt not_active IP Right Cessation
-
2002
- 2002-01-31 US US10/062,145 patent/US6559168B2/en not_active Expired - Fee Related
- 2002-11-20 US US10/300,950 patent/US6869945B2/en not_active Expired - Fee Related
- 2002-11-20 US US10/300,959 patent/US6894041B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 IS IS6844A patent/IS6844A/is unknown
- 2003-07-04 EC EC2003004683A patent/ECSP034683A/es unknown
- 2003-07-08 TN TNPCT/IB2001/002728A patent/TNSN03050A1/fr unknown
- 2003-07-21 MA MA27243A patent/MA26985A1/fr unknown
- 2003-07-25 ZA ZA200305769A patent/ZA200305769B/en unknown
- 2003-07-28 BG BG108039A patent/BG108039A/xx unknown
- 2003-07-29 CR CR7038A patent/CR7038A/es not_active Application Discontinuation
- 2003-07-30 NO NO20033398A patent/NO20033398L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BG108039A (en) | 2004-07-30 |
CN1489588A (zh) | 2004-04-14 |
US20030186974A1 (en) | 2003-10-02 |
US6559168B2 (en) | 2003-05-06 |
BR0116850A (pt) | 2004-02-25 |
AU2002222429A2 (fr) | 2002-08-12 |
US6894041B2 (en) | 2005-05-17 |
EE200300362A (et) | 2003-12-15 |
IL156412A0 (en) | 2004-01-04 |
NO20033398L (no) | 2003-09-29 |
ZA200305769B (en) | 2004-10-25 |
EA200300622A1 (ru) | 2003-12-25 |
OA12542A (en) | 2006-06-05 |
US20030130254A1 (en) | 2003-07-10 |
EP1355907A1 (fr) | 2003-10-29 |
NO20033398D0 (no) | 2003-07-30 |
US6869945B2 (en) | 2005-03-22 |
CR7038A (es) | 2004-04-22 |
JP2004518691A (ja) | 2004-06-24 |
CZ20031903A3 (cs) | 2004-07-14 |
CA2436551A1 (fr) | 2002-08-08 |
PL365443A1 (en) | 2005-01-10 |
MXPA03006886A (es) | 2003-11-13 |
MA26985A1 (fr) | 2004-12-20 |
IS6844A (is) | 2003-06-16 |
ECSP034683A (es) | 2003-08-29 |
HUP0401305A2 (hu) | 2004-10-28 |
US20020123520A1 (en) | 2002-09-05 |
WO2002060898A1 (fr) | 2002-08-08 |
KR20030072614A (ko) | 2003-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN03050A1 (fr) | Derives d'amides de thiazolyl -, oxazolyl - pyrrolyl - et imidazolyl - acides utiles comme inhibiteurs d' isozymes pde4. | |
AU2018200368B2 (en) | Compositions and methods of modulating 15-pgdh activity | |
AU2009282480B2 (en) | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof | |
CN100402492C (zh) | 前列腺癌、脱发和其他雄激素过多综合征的治疗和诊断中的雄激素受体抑制剂 | |
JP5643233B2 (ja) | プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン | |
CN103030597B (zh) | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 | |
CN112839940B (zh) | 氨基脲敏感性胺氧化酶抑制剂制备及其应用 | |
JP2021527088A (ja) | Her2阻害剤としてのシアノキノリンアミド化合物及び使用方法 | |
JP2021501123A (ja) | Egfrおよび/またはher2の阻害剤ならびに使用方法 | |
KR20160045925A (ko) | 퀴나졸린 유도체 | |
EP0469984B1 (fr) | Dérivés de la N-sulfonyl indoline, leur préparation, les compositions pharmaceutiques en contenant | |
CA2447305A1 (fr) | Nouveaux derives de 5-phenyl-1h-indole antagonistes des recepteurs de l'interleukine-8 | |
US4761404A (en) | Phospholipid analogs useful as PAF synthesis inhibitors | |
EP0600832A1 (fr) | Dérivés de diamino acid benzoique et diamino acid phthalique et leur application à titre des inhibiteurs de protéine kinase | |
EP1493739A1 (fr) | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
TW201739452A (zh) | 含有青蒿琥酯的組合物 | |
JPH06228108A (ja) | フタラジノン誘導体 | |
EP0303871B1 (fr) | Oxadiazolo pyrimidinones, leur préparation et leur utilisation en cosmétique et dermopharmacie | |
JPH06199786A (ja) | ジアミドフタリミドの置換誘導体 | |
JP7425925B2 (ja) | 二官能性化合物及び使用方法 | |
DE69908756T2 (de) | Matrix-metalloproteinase-inhibitoren | |
US5726311A (en) | 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same | |
CA2447184A1 (fr) | Derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 | |
EP4198017A1 (fr) | Dérivé de benzylamine, son procédé de préparation et son utilisation | |
WO2023224128A1 (fr) | Composition pharmaceutique pour le traitement ou la prévention d'une fibrose |